- Home
- DCBO vs GHRS Comparison
DCBO vs GHRS Comparison
Compare DCBO & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCBO
- GHRS
- Stock Information
- Founded
- DCBO 2016
- GHRS 2018
- Country
- DCBO Canada
- GHRS Ireland
- Employees
- DCBO N/A
- GHRS N/A
- Industry
- DCBO
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- DCBO
- GHRS Health Care
- Exchange
- DCBO Nasdaq
- GHRS Nasdaq
- Market Cap
- DCBO 893.7M
- GHRS 774.1M
- IPO Year
- DCBO 2020
- GHRS 2021
- Fundamental
- Price
- DCBO $30.62
- GHRS $13.11
- Analyst Decision
- DCBO Strong Buy
- GHRS Strong Buy
- Analyst Count
- DCBO 5
- GHRS 8
- Target Price
- DCBO $42.20
- GHRS $30.63
- AVG Volume (30 Days)
- DCBO 87.6K
- GHRS 185.8K
- Earning Date
- DCBO 11-07-2025
- GHRS 11-13-2025
- Dividend Yield
- DCBO N/A
- GHRS N/A
- EPS Growth
- DCBO 33.51
- GHRS N/A
- EPS
- DCBO 0.69
- GHRS N/A
- Revenue
- DCBO $230,502,000.00
- GHRS N/A
- Revenue This Year
- DCBO $13.02
- GHRS N/A
- Revenue Next Year
- DCBO $8.37
- GHRS N/A
- P/E Ratio
- DCBO $44.10
- GHRS N/A
- Revenue Growth
- DCBO 15.11
- GHRS N/A
- 52 Week Low
- DCBO $25.50
- GHRS $6.00
- 52 Week High
- DCBO $53.86
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- DCBO 49.44
- GHRS 48.12
- Support Level
- DCBO $29.91
- GHRS $11.83
- Resistance Level
- DCBO $30.68
- GHRS $14.59
- Average True Range (ATR)
- DCBO 0.80
- GHRS 0.79
- MACD
- DCBO -0.12
- GHRS -0.08
- Stochastic Oscillator
- DCBO 34.63
- GHRS 46.38
About DCBO Docebo Inc.
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.